title: Killing effect of interleukin-2 and interferon-alpha activated leukemic bone marrow in remission on K562 leukemic cells.
abstract: OBJECTIVE
  To evaluate the killing effect of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) activated bone marrow cells on K562 cells.
  
  
  METHODS
  Semi-solid colony and 3H-TdR incorporating method were used.
  
  
  RESULTS
  Bone marrow from leukemia patients in remission was activated in vitro with IL-2 for 3 days. The activated bone marrow (ABM) displayed killing effects of 0.31-2.30 logs on K562 cells. This killing effect was further increased to 0.30-3.15 logs when IFN-alpha added with IL-2 to the marrow for activation. IL-2 alone or in combination with IFN-alpha showed no inhibition of CFU-GM and K562 cells. Compared with IL-2 or IFN-alpha alone, the combination of the two cytokines could more effectively maintain the killing effect of ABM on leukemic cells.
  
  
  CONCLUSIONS
  IFN-alpha can augment the purging effect of IL-2 ABM and combination of the two cytokines can effectively maintain the cytotoxicity of ABM.
authors.affiliation: Institute of Hematology, Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.
authors.forename: C
authors.initials: C
authors.lastname: Li
authors.forename: W
authors.initials: W
authors.lastname: Yan
authors.forename: Y
authors.initials: Y
authors.lastname: Hao
authors.forename: M
authors.initials: M
authors.lastname: Han
authors.forename: L
authors.initials: L
authors.lastname: Qiu
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Han
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: S
authors.initials: S
authors.lastname: Feng
mesh_terms: D000208:Acute Disease; D001854:Bone Marrow Cells / Q000276:immunology*; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D020014:K562 Cells / Q000473:pathology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007938:Leukemia / Q000473:pathology*; D012074:Remission Induction
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2